Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
- 8 June 2004
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 53 (9) , 777-785
- https://doi.org/10.1007/s00262-004-0520-1
Abstract
Immunotherapy using either dendritic cells (DCs) or expanded cytotoxic T cells (CTLs) has received increased interest in the treatment of specific malignancies including metastatic breast cancer (MBC). DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated.Keywords
This publication has 0 references indexed in Scilit: